AdAlta (ASX:1AD) Margin of Safety % (DCF FCF Based): N/A (As of Jun. 26, 2026)


What is AdAlta Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

AdAlta's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

ASX:1AD vs VRTX, REGN, ALNY: Margin of Safety % (DCF FCF Based) Comparison

For the Biotechnology subindustry, AdAlta's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AdAlta Margin of Safety % (DCF FCF Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AdAlta's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where AdAlta's Margin of Safety % (DCF FCF Based) falls into.


AdAlta Business Description

Address 697 Burke Road, Suite 201, Camberwell, VIC, AUS, 3124
AdAlta Ltd is engaged in drug discovery and developing protein therapeutics, known as i-bodies, for treating a wide range of human diseases. The principal business of AdAlta is the discovery and development of next-generation cells and protein based therapeutics. The i-body candidate, AD-214, is being developed for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases. Its pipeline includes Fibrosis and CAR-T cancer therapeutics.